396
Views
6
CrossRef citations to date
0
Altmetric
ORIGINAL RESEARCH

Difference in Gastrointestinal Risk Associated with Use of GLP-1 Receptor Agonists: A Real-World Pharmacovigilance Study

, , &
Pages 155-163 | Published online: 13 Jan 2022

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

António Cabral Lopes, Fátima Roque, Olga Lourenço, Maria Teresa Herdeiro & Manuel Morgado. (2023) Gastrointestinal disorders potentially associated with Semaglutide: an analysis from the Eudravigilance Database. Expert Opinion on Drug Safety 22:6, pages 455-461.
Read now

Articles from other publishers (5)

Qian-Qian Zhou, Hai-Tao Xiao, Fan Yang, Yong-Dan Wang, Ping Li & Zu-Guo Zheng. (2023) Advancing targeted protein degradation for metabolic diseases therapy. Pharmacological Research 188, pages 106627.
Crossref
Hao Wu, Zongshi Lu, Runyao Chen, Quanfang Cai, Miaomiao Wang, Liting Zhang & Zhiming Zhu. (2023) Factors associated with gastrointestinal side effects after liraglutide treatment for type 2 diabetes. Frontiers in Endocrinology 14.
Crossref
Lulu Liu, Jia Chen, Lei Wang, Chen Chen & Li Chen. (2022) Association between different GLP-1 receptor agonists and gastrointestinal adverse reactions: A real-world disproportionality study based on FDA adverse event reporting system database. Frontiers in Endocrinology 13.
Crossref
Yamin Shu, Xucheng He, Pan Wu, Yanxin Liu, Yufeng Ding & Qilin Zhang. (2022) Gastrointestinal adverse events associated with semaglutide: A pharmacovigilance study based on FDA adverse event reporting system. Frontiers in Public Health 10.
Crossref
. (2022) Semaglutide and liraglutide have differing gastrointestinal ADR profiles. Reactions Weekly 1891:1, pages 12-12.
Crossref